Nemiroff Alex 4
4 · Praxis Precision Medicines, Inc. · Filed Nov 21, 2025
Insider Transaction Report
Form 4
Nemiroff Alex
General Counsel and Secretary
Transactions
- Exercise/Conversion
Common Stock
2025-11-20$133.65/sh+6,230$832,640→ 28,775.667 total - Sale
Common Stock
2025-11-20$192.53/sh−13,339$2,568,198→ 30,908.667 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-20−6,230→ 0 totalExercise: $133.65Exp: 2030-09-13→ Common Stock (6,230 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-20−5,652→ 2,347 totalExercise: $44.40Exp: 2033-01-12→ Common Stock (5,652 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-20−9,100→ 19,717 totalExercise: $56.94Exp: 2034-07-29→ Common Stock (9,100 underlying) - Exercise/Conversion
Common Stock
2025-11-20$44.40/sh+2,434$108,070→ 31,209.667 total - Sale
Common Stock
2025-11-20$190.86/sh−1,714$327,139→ 44,247.667 total - Exercise/Conversion
Common Stock
2025-11-20$44.40/sh+5,652$250,949→ 36,861.667 total - Exercise/Conversion
Common Stock
2025-11-20$83.85/sh+1,714$143,719→ 22,545.667 total - Sale
Common Stock
2025-11-20$193.23/sh−977$188,789→ 29,931.667 total - Sale
Common Stock
2025-11-20$194.30/sh−9,100$1,768,130→ 20,831.667 total - Exercise/Conversion
Common Stock
2025-11-20$56.94/sh+9,100$518,154→ 45,961.667 total - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-20−1,714→ 0 totalExercise: $83.85Exp: 2030-06-04→ Common Stock (1,714 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2025-11-20−2,434→ 0 totalExercise: $44.40From: 2023-01-12Exp: 2033-01-12→ Common Stock (2,434 underlying)
Footnotes (7)
- [F1]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $190.720 to $191.540. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F2]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $192.003 to $193.000. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $193.010 to $193.960. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
- [F4]This option was fully vested as of January 1, 2024.
- [F5]This option was fully vested as of September 9, 2024.
- [F6]The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.
- [F7]The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date.